›

Liver Disorders & Etiologies

Notes

Liver Disorders & Etiologies

Sections











Liver Diseases

Overview

Liver diseases can be acute or chronic; chronic is defined as inflammation
and/or fibrosis for at least 6 months. Recall that chronic liver disease is especially problematic when it leads to cirrhosis and portal hypertension.

We can categorize liver diseases by the type of injury they cause:

  • Hepatocellular injury, in which inflammation and necrosis affects the hepatocytes
  • Obstructive (aka, cholestatic) injury, in which bile flow is inhibited
  • Mixed injury

We can also categorize liver diseases by the types of morphological damage that occurs:

  • Toxic/necrosis
  • Fatty
  • Inflammatory (hepatitis)
  • Vascular injury
  • Cholestasis
  • Granuloma formation

Signs and symptoms of liver disease vary by stage:

Early in their course, most patients are asymptomatic.

As damage accumulates, they may experience right upper abdominal pain (aka, liver
pain), poor appetite/nausea (which can lead to malnutrition), and hyperbilirubinemia (particularly jaundice)

In end-stage liver disease, clinical manifestations of cirrhosis and portal hypertension, such as varices and ascites, may appear.

Diagnosis of liver disease is complex; we use a battery of blood tests to evaluate ALT
(alanine aminotransferase), AST (aspartate transaminase), AlkP (ALP, alkaline phosphatase), bilirubin, albumin, and prothrombin time.

Liver biopsy is the "gold standard" of liver disease evaluation, as the type and degree of damage is used to assess the stage and grade of disease.

"Grading" assesses liver disease the severity and prognosis for survival.
Examples include the Model for End-Stage Liver Disease (MELD) and the Child-Pugh score.

The Model for End-Stage Liver Disease (MELD), which is based on laboratory values, is used to evaluate patients in end-stage liver disease for organ transplant.

The Child-Pugh score is based on laboratory values and the presence/absence of signs of cirrhosis, including encephalopathy and ascites, to determine the severity of liver disease.

Chronic liver disease "staging" tells us how far along the disease has progressed (from inflammation, to fibrosis, to scarring & impaired function, to failure).

Drug-induced liver injury (DILI)

Acute or chronic liver injury in response to drugs, supplements, or medicinal herbs.

Damage can be direct or idiosyncratic; direct is dose-dependent and predictable, whereas idiosyncratic varies by individual, is not-dose dependent, and is not predictable. (be aware that some authors discuss direct, indirect, and idiosyncratic, others use "intrinsic" vs idiosyncratic).

Injury can lead to hepatitis or cholestatic injury, with various morphologies depending on the offending agent.

Acetaminophen is the most common cause of direct damage; when taken in large doses, acetaminophen metabolism releases reactive metabolites that accumulate and lead to hepatic apoptosis and necrosis.

Other common classes of drugs that cause hepatic injury include antibiotics (amoxicillin-clavulanate, sulfamethoxazole-trimethoprim, etc.); cardiovascular drugs (statins and amiodarone), and anti-seizure drugs (valproate, phenytoin).

Fatty liver

Fatty liver is a top cause of liver disease world-wide; it includes alcoholic and non-alcoholic etiologies.

Generalized progression:

First, fat accumulates in hepatocytes, which bloats the cells and displaces their nuclei.

Then, lipotoxicity from the accumulated fat causes inflammation and necrosis, which triggers repair processes; we may see Mallory-Denk bodies, which are cytoplasmic hyaline inclusions found in many chronic liver diseases.

Cycles of damage and repair lead to fibrosis, which, over time, can create scarring and impair liver functioning – this is cirrhosis, stage 3 liver disease.

Be aware that this progression does not occur in all individuals; the reasons for this are under investigation.

Alcoholic liver disease occurs in patients with chronic or binge drinking habits.

Lab results will show elevated AST to ALT ratios.

Alcoholic liver disease exists on a spectrum of mild to severe:

  1. Alcoholic fatty liver refers to the accumulation of fat in the hepatocytes; it is often asymptomatic.
  1. Alcoholic steatohepatitis refers to fatty liver with inflammation and fibrosis.
  1. Alcoholic hepatitis is the most severe form; patients may start to experience signs and symptoms of cirrhosis and portal hypertension, with possible fever. Chronic Hepatitis C infection is an important co-morbidity.

Alcohol cessation is always recommended. In the early stages, alcohol cessation can allow the liver to heal itself.

Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder associated with insulin resistance.

Patients should be checked for other metabolic disorders, and alcohol use should be ruled out.

Non-alcoholic fatty liver disease has essentially two pathways:

  1. Triglycerides accumulate in the hepatocytes and cause bloating and cell distortion (similar to the first image in our illustration).
  1. In some individuals, NAFLD progresses to non-alcoholic steatohepatitis (NASH), in which fat accumulation leads to lipotoxicity with eventual fibrosis and possibly cirrhosis (similar to the transition from alcoholic steatohepatitis to hepatitis).

Unfortunately, there are no broadly applicable treatments available for non-alcoholic fatty liver disease; weight loss is thought to reduce hepatic fat deposits and inflammation, and some pharmaceutical options are available for select patients (anti-diabetic drugs and vitamin supplements, which are not appropriate for everyone).

Viral hepatitis

Causes hepatocellular necrosis and can be acute or chronic, depending on the viral agent:

Hepatitis A and Hepatitis E are typically acute infections, whereas Hepatitis B, Hepatitis C, and Hepatitis B + D are chronic infections.

Look for elevated aminotransferases and specific antibodies in the blood, and note that viral hepatitis can cause fever as well as other symptoms.

For more on viral hepatitis, click here: Viral hepatitis

See microbiology tutorial: Viral Hepatits

Cholestatic liver diseases

Autoimmune disorders that result in bile accumulation, which damages hepatocytes.

Patients present with fatigue, itching, jaundice, and other manifestations of hyperbilirubinemia.

Primary biliary cholangitis (PBC) destroys the bile ducts.

We look for anti-mitochondrial antibodies in laboratory results; other unique signs include hypercholesterolemia and xanthomas.

PBC is most commonly diagnosed in women in their 40s-60s.

Primary sclerosing cholangitis is characterized by inflammation with scarring and narrowing (sclerosing) of the bile ducts, and is associated with irritable bowel disease.

The presence of p-ANCA supports the diagnosis.

Autoimmune hepatitis

This is a poorly understood condition characterized by necrosis and inflammation.

We can look for antinuclear antibodies (ANA) and antibodies against smooth muscle tissue (ASMA).

Because it is an autoimmune disorder, we treat it with immune suppressants.

Hemochromatosis

This is an inherited disorder of excess iron absorption from the small intestine.

We diagnose with blood iron and genetic tests.

Iron overload affects a variety of organ systems, and can cause hypogonadism (with sexual dysfunction), skin "bronzing," arthropathies, fatigue, diabetes mellitus, liver damage, and cardiomyopathy.

Wilson's disease

An inherited disorder of copper storage.

Excess copper particularly affects the liver, brain, and eyes, leading to abdominal pain, jaundice, weakness, movement and psychiatric disorders, and seizures.

Look for Kayser-Fleisher ring around the iris; these brownish-golden rings are created by copper deposition in the cornea, and typically begin their formation superiorly, under the eyelid.

For more on the genetic defects, mechanisms, and clinical outcomes of Wilson's disease, click here: Wilson's Disease

Hepatocellular cancer

The most common primary liver cancer, and is typically preceded by one of the chronic liver diseases we've discussed in this tutorial, especially when cirrhosis is present.

Thus, we need to regularly screen patients with chronic liver disease for cancer development.

Board Review

Fatty Liver Disease

Getting ready for boards? Review these concise, bulleted high yield reviews for your exam.

USMLE & COMLEX-USA

Nurse Practitioner (NP)

Physician Assistant (PA)

Internal Medicine (ABIM)

References

  • Agarwal, R, and R Baid. "Asterixis." Journal of Postgraduate Medicine 62, no. 2 (2016): 115–17. https://doi.org/10.4103/0022-3859.180572.
  • Anderson, Gregory J., and Edouard Bardou-Jacquet. "Revisiting Hemochromatosis: Genetic vs. Phenotypic Manifestations." Annals of Translational Medicine 9, no. 8 (April 2021): 731. https://doi.org/10.21037/atm-20-5512.
  • Ando, Yumi, and Janice H. Jou. "Nonalcoholic Fatty Liver Disease and Recent Guideline Updates." Clinical Liver Disease 17, no. 1 (2021): 23–28. https://doi.org/10.1002/cld.1045.
  • Appenrodt, Beate, and Frank Lammert. "Renal Failure in Patients with Liver Cirrhosis: Novel Classifications, Biomarkers, Treatment." Visceral Medicine 34, no. 4 (2018): 246–53. https://doi.org/10.1159/000492587.
  • "Approach to the Patient with Abnormal Liver Biochemical and Function Tests - UpToDate." Accessed July 12, 2022. https://www-uptodate-com.proxy.ulib.uits.iu.edu/contents/approach-to-the-patient-with-abnormal-liver-biochemical-and-function-tests?search=drug%20induced%20liver%20injury&topicRef=3571&source=see_link.
  • August, Last reviewed/updated: and 2018. "Stages of Cirrhosis - Viral Hepatitis and Liver Disease." Guide. Accessed June 15, 2022. https://www.hepatitis.va.gov/cirrhosis/background/stages.asp.
  • NORD (National Organization for Rare Disorders). "Autoimmune Hepatitis." Accessed June 23, 2022. https://rarediseases.org/rare-diseases/autoimmune-hepatitis/.
  • Bansal, Kamna, Meghana Gore, and Sahil Mittal. "Hepatopulmonary Syndrome." In StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. http://www.ncbi.nlm.nih.gov/books/NBK562169/.
  • Beers, Joyce J B C van, Ger H Koek, and Jan G M C Damoiseaux. "The Role of Autoantibodies in the Diagnosis of Autoimmune Liver Disease: Lessons Learned from Clinical Practice." The Journal of Applied Laboratory Medicine 7, no. 1 (January 1, 2022): 259–67. https://doi.org/10.1093/jalm/jfab099.
  • Bera, Chinmay, and Florence Wong. "Management of Hepatorenal Syndrome in Liver Cirrhosis: A Recent Update." Therapeutic Advances in Gastroenterology 15 (January 1, 2022): 17562848221102680. https://doi.org/10.1177/17562848221102679.
  • Butterworth, Roger F. "Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology." Drugs 79, no. 1 (February 1, 2019): 17–21. https://doi.org/10.1007/s40265-018-1017-0.
  • Chiejina, Maria, Pujitha Kudaravalli, and Hrishikesh Samant. "Ascites." In StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. http://www.ncbi.nlm.nih.gov/books/NBK470482/.
  • "Cirrhosis - ClinicalKey." Accessed June 24, 2022. https://www-clinicalkey-com.proxy.ulib.uits.iu.edu/#!/content/book/3-s2.0-B9781455707478000509.
  • Merck Manuals Professional Edition. "Cirrhosis - Hepatic and Biliary Disorders." Accessed June 14, 2022. https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/fibrosis-and-cirrhosis/cirrhosis.
  • "Cirrhosis in Adults: Etiologies, Clinical Manifestations, and Diagnosis - UpToDate." Accessed June 24, 2022. https://www-uptodate-com.proxy.ulib.uits.iu.edu/contents/cirrhosis-in-adults-etiologies-clinical-manifestations-and-diagnosis?search=cirrhosis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
  • "Clinical Course and Diagnosis of Drug Induced Liver Disease." In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012. http://www.ncbi.nlm.nih.gov/books/NBK548733/.
  • D'Amico, Gennaro, Mauro Bernardi, and Paolo Angeli. "Towards a New Definition of Decompensated Cirrhosis." Journal of Hepatology 76, no. 1 (January 2022): 202–7. https://doi.org/10.1016/j.jhep.2021.06.018.
  • "Drug-Induced Liver Injury: Pathogenesis, Epidemiology, Clinical Features, and Practical Management - ClinicalKey." Accessed July 8, 2022. https://www-clinicalkey-com.proxy.ulib.uits.iu.edu/#!/content/playContent/1-s2.0-S0953620521003757?returnurl=null&referrer=null.
  • Fischer, Hans-Peter, and Diane Goltz. "Autoimmune Lebererkrankungen." Der Pathologe 41, no. 5 (September 2020): 444–56. https://doi.org/10.1007/s00292-020-00807-7.
  • Gandhi, Kejal D, Pahnwat Tonya Taweesedt, Munish Sharma, and Salim Surani. "Hepatopulmonary Syndrome: An Update." World Journal of Hepatology 13, no. 11 (November 27, 2021): 1699–1706. https://doi.org/10.4254/wjh.v13.i11.1699.
  • Girelli, Domenico, Fabiana Busti, Pierre Brissot, Ioav Cabantchik, Martina U. Muckenthaler, and Graça Porto. "Hemochromatosis Classification: Update and Recommendations by the BIOIRON Society." Blood 139, no. 20 (May 19, 2022): 3018–29. https://doi.org/10.1182/blood.2021011338.
  • Gracia-Sancho, Jordi, this link will open in a new window Link to external site, Giusi Marrone, Anabel Fernández-Iglesias, and this link will open in a new window Link to external site. "Hepatic Microcirculation and Mechanisms of * Portal Hypertension." Nature Reviews. Gastroenterology & Hepatology 16, no. 4 (April 2019): 221–34. https://doi.org/10.1038/s41575-018-0097-3.
  • Hanna, Robert F., Diego A. Aguirre, Norbert Kased, Shawn C. Emery, Michael R. Peterson, and Claude B. Sirlin. "Cirrhosis-Associated Hepatocellular Nodules: Correlation of Histopathologic and MR Imaging Features." RadioGraphics 28, no. 3 (May 2008): 747–69. https://doi.org/10.1148/rg.283055108.
  • "HARRISON Principles of Internal Medicine 20th Edition.Pdf." Accessed July 7, 2022.
  • American Liver Foundation. "Hepatorenal Syndrome - ALF Disease Information Center." Accessed June 23, 2022. https://liverfoundation.org/for-patients/about-the-liver/diseases-of-the-liver/hepatorenal-syndrome/.
  • Hosseini, Nooshin, Julia Shor, and Gyongyi Szabo. "Alcoholic Hepatitis: A Review." Alcohol and Alcoholism 54, no. 4 (July 1, 2019): 408–16. https://doi.org/10.1093/alcalc/agz036.
  • Huang, Tony (Dazhong), Jason Behary, and Amany Zekry. "Non-Alcoholic Fatty Liver Disease: A Review of Epidemiology, Risk Factors, Diagnosis and Management." Internal Medicine Journal 50, no. 9 (2020): 1038–47. https://doi.org/10.1111/imj.14709.
  • Ipsen, David Højland, Jens Lykkesfeldt, and Pernille Tveden-Nyborg. "Molecular Mechanisms of Hepatic Lipid Accumulation in Non-Alcoholic Fatty Liver Disease." Cellular and Molecular Life Sciences 75, no. 18 (September 1, 2018): 3313–27. https://doi.org/10.1007/s00018-018-2860-6.
  • Khomich, Olga, Alexander V. Ivanov, and Birke Bartosch. "Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis." Cells 9, no. 1 (January 2020): 24. https://doi.org/10.3390/cells9010024.
  • Kowdley, Kris V., Kyle E. Brown, Joseph Ahn, and Vinay Sundaram. "ACG Clinical Guideline: Hereditary Hemochromatosis." Official Journal of the American College of Gastroenterology | ACG 114, no. 8 (August 2019): 1202–18. https://doi.org/10.14309/ajg.0000000000000315.
  • Krishna, Murli. "Patterns of Necrosis in Liver Disease." Clinical Liver Disease 10, no. 2 (August 30, 2017): 53–56. https://doi.org/10.1002/cld.653.
  • Krowka, Michael J. "Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease." Clinical Liver Disease 15, no. Suppl 1 (March 2, 2020): S13–24. https://doi.org/10.1002/cld.846.
  • Lackner, Carolin, Rudolf E. Stauber, Susan Davies, Helmut Denk, Hans Peter Dienes, Viviane Gnemmi, Maria Guido, et al. "Development and Prognostic Relevance of a Histologic Grading and Staging System for Alcohol-Related Liver Disease." Journal of Hepatology 75, no. 4 (October 1, 2021): 810–19. https://doi.org/10.1016/j.jhep.2021.05.029.
  • Lim, Hong Kiat, Gary P. Jeffrey, Grant A. Ramm, and Carolina Soekmadji. "Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles." Frontiers in Cellular and Infection Microbiology 10 (2020). https://www.frontiersin.org/article/10.3389/fcimb.2020.587628.
  • Linzay, Catherine D., Bashar Sharma, and Sudha Pandit. "Autoimmune Hepatitis." In StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. http://www.ncbi.nlm.nih.gov/books/NBK459186/.
  • "Liver Fibrosis: Pathophysiology and Clinical Implications." Accessed June 14, 2022. https://doi.org/10.1002/wsbm.1499.
  • "Liver Function Tests." Accessed June 27, 2022. https://stanfordhealthcare.org/medical-conditions/liver-kidneys-and-urinary-system/drug-induced-hepatitis/diagnosis/liver-function-tests.html.
  • "Liver Function Tests - Mayo Clinic." Accessed June 27, 2022. https://www.mayoclinic.org/tests-procedures/liver-function-tests/about/pac-20394595.
  • "Manifestations of Cirrhosis - UpToDate." Accessed June 24, 2022. https://www-uptodate-com.proxy.ulib.uits.iu.edu/contents/image/print?imageKey=GAST%2F90943&topicKey=1253&search=cirrhosis&rank=1~150&source=see_link.
  • Maurice, James, and Pinelopi Manousou. "Non-Alcoholic Fatty Liver Disease." Clinical Medicine 18, no. 3 (June 2018): 245–50. https://doi.org/10.7861/clinmedicine.18-3-245.
  • McConnell, Matthew, and Yasuko Iwakiri. "Biology of Portal Hypertension." Hepatology International 12, no. S1 (February 2018): 11–23. https://doi.org/10.1007/s12072-017-9826-x.
  • American College of Gastroenterology. "Medications and the Liver." Accessed June 28, 2022. https://gi.org/topics/medications-and-the-liver/.
  • "Metabolic and Toxic Conditions of the Liver - ClinicalKey." Accessed June 24, 2022. https://www-clinicalkey-com.proxy.ulib.uits.iu.edu/#!/content/book/3-s2.0-B9781437709254000274.
  • Mieli-Vergani, Giorgina, Diego Vergani, Albert J. Czaja, Michael P. Manns, Edward L. Krawitt, John M. Vierling, Ansgar W. Lohse, and Aldo J. Montano-Loza. "Autoimmune Hepatitis." Nature Reviews Disease Primers 4, no. 1 (June 7, 2018): 18017. https://doi.org/10.1038/nrdp.2018.17.
  • Mitra, Souveek, Arka De, and Abhijit Chowdhury. "Epidemiology of Non-Alcoholic and Alcoholic Fatty Liver Diseases." Translational Gastroenterology and Hepatology 5 (April 5, 2020): 16. https://doi.org/10.21037/tgh.2019.09.08.
  • Møller, Søren, and Flemming Bendtsen. "The Pathophysiology of Arterial Vasodilatation and Hyperdynamic Circulation in Cirrhosis." Liver International 38, no. 4 (2018): 570–80. https://doi.org/10.1111/liv.13589.
  • Nardelli, Silvia, Oliviero Riggio, Stefania Gioia, Marta Puzzono, Giuseppe Pelle, and Lorenzo Ridola. "Spontaneous Porto-Systemic Shunts in Liver Cirrhosis: Clinical and Therapeutical Aspects." World Journal of Gastroenterology 26, no. 15 (April 21, 2020): 1726–32. https://doi.org/10.3748/wjg.v26.i15.1726.
  • O'Leary, Jacqueline G., Charles S. Greenberg, Heather M. Patton, and Stephen H. Caldwell. "AGA Clinical Practice Update: Coagulation in Cirrhosis." Gastroenterology 157, no. 1 (July 2019): 34-43.e1. https://doi.org/10.1053/j.gastro.2019.03.070.
  • Pape, Simon, Christoph Schramm, and Tom JG Gevers. "Clinical Management of Autoimmune Hepatitis." United European Gastroenterology Journal 7, no. 9 (November 1, 2019): 1156–63. https://doi.org/10.1177/2050640619872408.
  • Parthasarathy, Gopanandan, Xavier Revelo, and Harmeet Malhi. "Pathogenesis of Nonalcoholic Steatohepatitis: An Overview." Hepatology Communications 4, no. 4 (2020): 478–92. https://doi.org/10.1002/hep4.1479.
  • Patel, Roshan, and Matthew Mueller. "Alcoholic Liver Disease." In StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. http://www.ncbi.nlm.nih.gov/books/NBK546632/.
  • "Pathogenesis of Alcohol-Associated Liver Disease - UpToDate." Accessed June 27, 2022. https://www-uptodate-com.proxy.ulib.uits.iu.edu/contents/pathogenesis-of-alcohol-associated-liver-disease?search=Pathogenesis%20of%20alcohol-associated%20liver%20disease&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
  • "Pathology Outlines - Cirrhosis." Accessed June 15, 2022. https://www.pathologyoutlines.com/topic/livercirrhosis.html.
  • "Pathophysiology of Decompensated Cirrhosis: Portal Hypertension, Circulatory Dysfunction, Inflammation, Metabolism and Mitochondrial Dysfunction | Elsevier Enhanced Reader." Accessed June 14, 2022. https://doi.org/10.1016/j.jhep.2021.01.002.
  • Peters, Lynn, Sanne Burkert, and Beate Grüner. "Parasites of the Liver – Epidemiology, Diagnosis and Clinical Management in the European Context." Journal of Hepatology 75, no. 1 (July 2021): 202–18. https://doi.org/10.1016/j.jhep.2021.02.015.
  • Polyzos, Stergios A., Eun Seok Kang, Chrysoula Boutari, Eun-Jung Rhee, and Christos S. Mantzoros. "Current and Emerging Pharmacological Options for the Treatment of Nonalcoholic Steatohepatitis." Metabolism 111 (October 2020): 154203. https://doi.org/10.1016/j.metabol.2020.154203.
  • Pouwels, Sjaak, Nasser Sakran, Yitka Graham, Angela Leal, Tadeja Pintar, Wah Yang, Radwan Kassir, Rishi Singhal, Kamal Mahawar, and Dharmanand Ramnarain. "Non-Alcoholic Fatty Liver Disease (NAFLD): A Review of Pathophysiology, Clinical Management and Effects of Weight Loss." BMC Endocrine Disorders 22, no. 1 (March 14, 2022): 63. https://doi.org/10.1186/s12902-022-00980-1.
  • "ResearchGate." Accessed June 15, 2022. https://www.researchgate.net/publication/6258837_Matrix_Metalloproteinase_Gene_Delivery_for_Liver_Fibrosis/link/0fcfd50e73033f3244000000/download.
  • Roerecke, Michael, Afshin Vafaei, Omer SM Hasan, Bethany R Chrystoja, Marcus Cruz, Roy Lee, Manuela G Neuman, and Jürgen Rehm. "Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis." The American Journal of Gastroenterology 114, no. 10 (October 2019): 1574–86. https://doi.org/10.14309/ajg.0000000000000340.
  • Samant, Hrishikesh, and Jiten P. Kothadia. "Spider Angioma." In StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. http://www.ncbi.nlm.nih.gov/books/NBK507818/.
  • Shao, Qihui, Xinyu Mao, Zhixuan Zhou, Cong Huai, and Zhiling Li. "Research Progress of Pharmacogenomics in Drug-Induced Liver Injury." Frontiers in Pharmacology 12 (2021). https://www.frontiersin.org/articles/10.3389/fphar.2021.735260.
  • Simonetto, Douglas A., Mengfei Liu, and Patrick S. Kamath. "Portal Hypertension and Related Complications: Diagnosis and Management." Mayo Clinic Proceedings 94, no. 4 (April 2019): 714–26. https://doi.org/10.1016/j.mayocp.2018.12.020.
  • Singal, Ashwani K., Ramon Bataller, Joseph Ahn, Patrick S. Kamath, and Vijay H. Shah. "ACG Clinical Guideline: Alcoholic Liver Disease." The American Journal of Gastroenterology 113, no. 2 (February 2018): 175–94. https://doi.org/10.1038/ajg.2017.469.
  • Sucher, Elisabeth, Robert Sucher, Tanja Gradistanac, Gerald Brandacher, Stefan Schneeberger, and Thomas Berg. "Autoimmune Hepatitis—Immunologically Triggered Liver Pathogenesis—Diagnostic and Therapeutic Strategies." Journal of Immunology Research 2019 (November 25, 2019): e9437043. https://doi.org/10.1155/2019/9437043.
  • Tsoris, Andrea, and Clinton A. Marlar. "Use Of The Child Pugh Score In Liver Disease." In StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. http://www.ncbi.nlm.nih.gov/books/NBK542308/.
  • Uetrecht, Jack. "Mechanistic Studies of Idiosyncratic DILI: Clinical Implications." Frontiers in Pharmacology 10 (2019). https://www.frontiersin.org/articles/10.3389/fphar.2019.00837.
  • Yoshiji, Hitoshi, Sumiko Nagoshi, Takemi Akahane, Yoshinari Asaoka, Yoshiyuki Ueno, Koji Ogawa, Takumi Kawaguchi, et al. "Evidence-Based Clinical Practice Guidelines for Liver Cirrhosis 2020." Journal of Gastroenterology 56, no. 7 (July 2021): 593–619. https://doi.org/10.1007/s00535-021-01788-x.
  • Zackria, Rasiq, and Savio John. "Asterixis." In StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. http://www.ncbi.nlm.nih.gov/books/NBK535445/.
  • "Approach to the Patient with Abnormal Liver Biochemical and Function Tests - UpToDate." Accessed July 12, 2022. https://www-uptodate-com.proxy.ulib.uits.iu.edu/contents/approach-to-the-patient-with-abnormal-liver-biochemical-and-function-tests?search=drug%20induced%20liver%20injury&topicRef=3571&source=see_link.
  • NORD (National Organization for Rare Disorders). "Autoimmune Hepatitis." Accessed June 23, 2022. https://rarediseases.org/rare-diseases/autoimmune-hepatitis/.
  • "Cirrhosis - ClinicalKey." Accessed June 24, 2022. https://www-clinicalkey-com.proxy.ulib.uits.iu.edu/#!/content/book/3-s2.0-B9781455707478000509.
  • Merck Manuals Professional Edition. "Cirrhosis - Hepatic and Biliary Disorders." Accessed June 14, 2022. https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/fibrosis-and-cirrhosis/cirrhosis.
  • "Cirrhosis in Adults: Etiologies, Clinical Manifestations, and Diagnosis - UpToDate." Accessed June 24, 2022. https://www-uptodate-com.proxy.ulib.uits.iu.edu/contents/cirrhosis-in-adults-etiologies-clinical-manifestations-and-diagnosis?search=cirrhosis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
  • "Clinical Course and Diagnosis of Drug Induced Liver Disease." In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012. http://www.ncbi.nlm.nih.gov/books/NBK548733/.
  • "Drug-Induced Liver Injury: Pathogenesis, Epidemiology, Clinical Features, and Practical Management - ClinicalKey." Accessed July 8, 2022. https://www-clinicalkey-com.proxy.ulib.uits.iu.edu/#!/content/playContent/1-s2.0-S0953620521003757?returnurl=null&referrer=null.